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Acarbose is an antidiabetic drug which acts by inhibiting a-amylase and a-glucosidase
activities but with deleterious side effects. Gallic acid (GA) is a phenolic acid that is
widespread in plant foods. We therefore investigated the influence of GA on a-amylase and
a-glucosidase inhibitory properties of acarbose (in vitro). Aqueous solutions of acarbose and
GA were prepared to a final concentration of 25mM each. Thereafter, mixtures of the
samples (50% acarbose þ 50% GA; 75% acarboseþ 25% GA; and 25% acarboseþ 75% GA)
were prepared. The results revealed that the combination of 50% acarbose and 50% GA
showed the highest a-glucosidase inhibitory effect, while 75% acarboseþ 25% GA showed
the highest a-amylase inhibitory effect. Furthermore, all the samples caused the inhibition
of Fe2þ-induced lipid peroxidation (in vitro) in rat pancreatic tissue homogenate, with the
combination of 50% acarbose and 50% GA causing the highest inhibition. All the samples
also showed antioxidant properties (reducing property, 2,2'-azino-bis (-3-ethyl-
benzthiazoline-6-sulphonate [ABTS*] and 1,1-diphenyl-2-picrylhydrazyl [DPPH] free radi-
cals scavenging abilities, and Fe2þ chelating ability). Therefore, combinations of GA with
acarbose could be employed as antidiabetic therapy, with a possible reduction of side ef-
fects of acarbose; nevertheless, the combination of 50% acarbose and 50% GA seems the
best.
Copyright © 2016, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Diabetes Mellitus (DM) commonly referred to as diabetes is a
group of metabolic diseases characterized by hyperglycemia
(high blood glucose levels over a prolonged period), eitherochemistry, Federal Univ
, goboh@futa.edu.ng (G. O
ministration, Taiwan. Publi
.org/licenses/by-nc-nd/4.0/because the pancreas does not produce enough insulin, or
because the cells do not respond to the insulin that is pro-
duced [1]. The main symptoms of high blood glucose include
polyuria (frequent urination), polydipsia (increased thirst),
and polyphagia (increased hunger). If left untreated, this
chronic disease can cause many complications [2]. Type 2 DMersity of Technology, Private Mail Bag 704, Akure 340001, Nigeria.
boh).
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Figure 1 e Structural formula of gallic acid (3,4,5-
trihydroxybenzoic acid).
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acterized by insulin resistance, which may be combined with
relatively reduced insulin secretion [1], leading to hypergly-
cemia and ultimatelymalfunctioning of the pancreatic b-cells.
Prolonged hyperglycemia results in increased generation of
reactive oxygen species (ROS) and impairment of endogenous
antioxidants [4]. Oxidative stress resulting from the hyper-
glycemic condition in T2DM has been implicated in the
impairment of the pancreatic b-cells and diabetes complica-
tions such as diabetes nephropathy [5], diabetes retinopathy
[6,7], and diabetes neuropathy [8].
A practical approach to reducing the postprandial hyper-
glycemia is to retard the absorption of carbohydrates after
food intake [9]. This could be achieved through the inhibition
of a-amylase and a-glucosidase present in the gastrointestinal
tract [10]. Inhibitors of these enzymes slow down carbohy-
drate digestion time, causing a reduction in the rate of glucose
absorption and consequently blunting the postprandial
plasma glucose rise [11]. The dietary polysaccharides are first
broken down to monosaccharides by certain gastrointestinal
enzymes, since only monosaccharides can be absorbed from
the intestinal lumen. Polysaccharides are hydrolyzed to oli-
gosaccharides and disaccharides by a-amylase and intestinal
a-glucosidase further hydrolyzes it to glucose before being
absorbed into the intestinal epithelium entering the blood
circulation [12]. Therefore, therapeutic inhibitors of a-gluco-
sidase and a-amylase such as acarbose, miglitol, voglibose,
nojirimycin, and 1-deoxynojirimycin have been developed for
the management of hyperglycemia and T2DM [9].
Acarbose is an oral a-glucosidase and a-amylase inhibitor
used in the management of T2DM [13,14]. Acarbose is a
complex oligosaccharide known to reduce and slow down the
intestinal absorption of glucose, which subsequently reduces
the postprandial rise of blood glucose levels in T2DM patients
[15]. T2DM patients are often placed on a recommended
acarbose starter dose of 50 mg thrice daily, which may be
increased to a maintenance dose of 100e200 mg thrice daily
after 6e8 weeks if necessary [13]. Nevertheless, the use of
acarbose is not without its attendant side effects; the major
ones being diarrhea and flatulence as a result of prolonged
inhibition of starch hydrolysis [16]. Furthermore, excessive
pancreatic a-amylase inhibition as a result of prolonged use of
acarbose can result in the accumulation of undigested car-
bohydrate in the colon and serving as substrate for bacteria
fermentation [16,17]; the consequences of this are severe
gastrointestinal complications such as flatulence, diarrhea,
and abdominal distention [16].
In recent years, there has been an increased interest in the
potential applications of antioxidants for medicinal purposes,
as information linking the pathogenesis of several human
diseases to oxidative stress abounds [18]. Natural food sources
are known to contain antioxidant compounds that can scav-
enge free radicals and these dietary antioxidants have
generated particular interest as defenses against degenerative
diseases [19,20]. Phenolic compounds are found abundant in
many plant foods and most of them have shown antioxidant
properties in both in vitro [21] and in vivo studies [22]. Gallic
acid or 3,4,5-trihydroxybenzoic acid (Figure 1) is a phenolic
acid which is abundantly distributed in many food sources
such as fruits, vegetables, spices, and tea [23]. Recent studieshave documented that gallic acid and its esters [e.g., (e)-epi-
gallocatechin-3-gallate] exert antioxidant, anticancer, anti-
viral, and many other biological effects [24,25]. Consequently,
this study investigated the effect of gallic acid on the inhibi-
tory properties of acarbose on the activities of key enzymes (a-
glucosidase and a-amylase) linked to T2DM (in vitro).2. Methods
2.1. Sample collection
Acarbose was purchased from Glenmark Generics Pharma-
ceutical Europe Limited, Mumbai, India. Gallic acid was pur-
chased from Sigma Aldrich Co. (St. Louis, MO, USA).
2.2. Chemicals and reagents
Chemical reagents such as Trolox (6-hydroxy-2,5,7,8-
tetramethylchroman-2-carboxylic acid), 2, 2-diphenyl-1pic-
rylhydrazyl (DPPH), thiobarbituric acid, gallic acid, porcine
pancreatic a-amylase, and 1,10-phenanthroline were pro-
cured from Sigma Aldrich Co. Trichloroacetic acid was
sourced from Sigma Aldrich, Chemie GmbH (Steinheim, Ger-
many). Hydrogen peroxide, methanol, acetic acid, hydro-
chloric acid, aluminium chloride, potassium acetate, sodium
dodecyl sulfate, iron (II) sulfate, potassium ferrycyanide, and
ferric chloride were sourced from BDH Chemicals Ltd., (Poole,
England, UK). Ascorbic acid and starchwere products ofMerck
(Darmstadt, Germany). Except stated otherwise, all other
chemicals and reagents were of analytical grades and the
water used was glass distilled.
2.3. Sample preparation
Acarbose and gallic acid were dissolved in distilled water to a
final concentration of 25mM. Thereafter, sample mixtures
were prepared as follows: S1¼ 100% acarbose (25mM);
S2¼ 100% gallic acid (25mM); S3¼ 50% acarboseþ 50% gallic
acid; S4¼ 75% acarboseþ 25% gallic acid; and S5¼ 25%
acarboseþ 75% gallic acid. All samples were kept in the
refrigerator at 4C for subsequent analysis.
2.4. a-Glucosidase activity assay
Appropriate dilution of the sample (50 mL) and 100 mL of a-
glucosidase solution (effective concentration 3.2.1.20; 1.0 U/
mL) in 0.1M phosphate buffer (pH 6.9) was incubated at 25C
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glucopyranoside solution in 0.1M phosphate buffer (pH 6.9)
was added. Themixtureswere incubated at 25C for 5minutes
and the absorbance was read at 405 nm in the spectropho-
tometer (Jenway 6305 model, Bibby Scientific, Staffordshine,
United Kingdom). The a-glucosidase inhibitory activity was
expressed as percentage inhibition [26].
2.5. a-Amylase activity assay
The aqueous sample dilution (500 mL) and 500 mL of 0.02M
sodium phosphate buffer (pH 6.9 with 0.006M NaCl) contain-
ing 0.5 mg/mL Hog pancreatic a-amylase (effective concen-
tration 3.2.1.1) were incubated at 25C for 10 minutes.
Thereafter, 500 mL of 1% starch solution in 0.02M sodium
phosphate buffer (pH 6.9 with 0.006MNaCl) was added to each
reaction mixture. The reaction mixtures were incubated at
25C for 10minutes and stoppedwith 1.0mL of dinitrosalicylic
acid color reagent. Thereafter, the mixture was incubated in a
boiling water bath for 5 minutes, and cooled to room tem-
perature. The reaction mixture was then diluted by adding
10 mL of distilled water, and the absorbance was measured at
540 nm. The reference samples included all other reagents
and the enzyme with the exception of the test sample. The
percentage enzyme inhibitory activity of the extract was
subsequently calculated [27].
2.6. Fe2þ chelation assay
The Fe2þ chelating ability of the samples was determined
using the modified method of Puntel et al [28]. Freshly pre-
pared 500 mmol/L FeSO4 (150 mL) was added to a reaction
mixture containing 168 mL of 0.1 mol/L Tris-HCl (pH 7.4), 218-
mL saline, and the extract (0e100 mL). The reactionmixturewas
incubated for 5 minutes before the addition of 13 mL of 0.25%
1:10 phenanthroline (weight/volume). The absorbance was
subsequently measured at 510 nm in a spectrophotometer.
The Fe2þ chelating ability of the extract was subsequently
calculated as percentage of the control.
2.7. Lipid peroxidation assay
2.7.1. Experimental animals
Albino rats weighing 200e210 g were purchased from the
breeding colony of Department of Veterinary Medicine, Uni-
versity of Ibadan, Ibadan, Nigeria. Rats were maintained at
25

C, on a 12 hour light/12 hour dark cycle, with free access to
food and water. They were acclimatized under these condi-
tions for 1 week before the experiment.
2.7.2. Preparation of tissue homogenate
The rat was immobilized by cervical dislocation and the
pancreatic tissue was rapidly isolated and placed on ice and
weighed. This tissue was subsequently homogenized in cold
saline (1/10 weight/volume) with about 10-up-and-down
strokes at approximately 1200 rev/min in a Teflon glass ho-
mogenizer (Mexxcare, mc14 362, Aayu-shi Design Pvt. Ltd.,
Uttar Pradesh, India). The homogenate was centrifuged for 10
minutes at 3000g in a refrigerated centrifuge (KX3400C, KEN-
XIN Intl. Co., Hong Kong) at 4C to yield a pellet that wasdiscarded, and a low-speed supernatant (LSS), which was kept
for a lipid peroxidation assay [29].
2.7.3. Inhibition of lipid peroxidation and thiobarbituric acid
reactions
The lipid peroxidation assay was carried out using the modi-
fied method of Ohkawa et al [30]. Briefly 100 mL of LSS fraction
was mixed with a reaction mixture containing 30 mL of 0.1M
pH 7.4 Tris-HCl buffer, extract (0e100 mL), and 30 mL of 250mM
freshly prepared FeSO4. The volume wasmade up to 300 mL by
water before incubation at 37C for 1 hour. The color reaction
was developed by adding 300 mL 8.1% sodium dodecyl sulfate
to the reaction mixture containing LSS and this was subse-
quently followed by the addition of 600 mL of acetic acid/HCl
(pH 3.4) mixture and 600-mL 0.8% thiobarbituric acid. This
mixture was incubated at 100

C for 1 hour. The thiobarbituric
acid reactive species produced was measured at 532 nm in a
UV/visible spectrophotometer (Jenway 6305 model, Jenway
6305 model, Bibby Scientific, Staffordshine, United Kingdom)
and expressed using malondialdehyde (MDA) equivalent.
2.8. Determination of ferric reducing antioxidant
property
The reducing property of the samples was determined by
assessing its ability to reduce a FeCl3 solution as described by
Pulido et al [31]. A 2.5-mL aliquot of the extract was mixed
with 2.5 mL of 200mM sodium phosphate buffer (pH 6.6) and
2.5 mL of 1% potassium ferricyanide. The mixture was incu-
bated at 50C for 20 minutes and thereafter 2.5 mL of 10%
trichloroacetic acid was added. This mixture was centrifuged
at 805g for 10 minutes; 5 mL of the supernatant was mixed
with an equal volume of water and 1 mL of 0.1% ferric chlo-
ride. The absorbance was measured at 700 nm in the spec-
trophotometer after allowing the solution to stand for 30
minutes. The reducing property was subsequently calculated
using an ascorbic acid equivalent (AAE).
2.9. 2, 20-Azino-bis(-3-ethylbenzthiazoline-6-
sulphonate ) scavenging ability
Trolox equivalent antioxidant capacity (TEAC) of the samples
was determined by their 2, 20-azino-bis(-3-ethylbenzthia
zoline-6-sulphonate (ABTSþ) scavenging ability according to
the method described by Re et al [32]. The ABTSþ was gener-
ated by reacting (7 mmol/L) ABTSþ aqueous solution with
K2S2O8 (2.45 mmol/L, final concentration) in the dark for 16
hours and adjusting the absorbance at 734 nm to 0.700 in a
spectrophotometer with ethanol. An appropriate dilution of
0.2 mL extract was added to 2.0 mL ABTSþ solution and the
absorbance was measured at 734 nm in a spectrophotometer
after 15 minutes. The Trolox equivalent antioxidant capacity
was subsequently calculated using Trolox as the standard.
2.10. 1, 1-Diphenyle2-picrylhydrazyl) free radical
scavenging ability
The scavenging ability of the extracts against 1, 1-diphenyle2-
picrylhydrazyl (DPPH) free radical was evaluated as described
by Gyamfi et al [33] with slight modifications. One milliliter of
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extract. The mixture was left in the dark for 30 minutes and
the absorbance was measured at 516 nm in the spectropho-
tometer. The DPPH free radical scavenging ability was subse-
quently calculated as percentage of the control.
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h2.11. Statistical analysis
The results of replicate readingswere pooled and expressed as
mean± standard deviation and the least significance differ-
ence [34]. One-way analysis of variance was used to compare
the mean and significance was accepted at p < 0.05.S1 S2 S3
Sample
S4 S5
Figure 3 e Effect of gallic acid on a-amylase inhibitory
ability of acarbose (in vitro). Bars represent
mean± standard deviation of triplicate readings (n¼ 3).
* Mean values are significantly different (p< 0.05)
compared with S1. ** Mean values are significantly
different (p< 0.05) compared with S2. S1¼ 100% acarbose
(25mM); S2¼ 100% gallic acid (25mM); S3¼ 50%
acarboseþ 50% gallic acid; S4¼ 75% acarboseþ 25% gallic
acid; S5¼ 25% acarboseþ 75% gallic acid.3. Results
The effect of gallic acid on a-glucosidase inhibitory properties
of acarbose (Figure 2) revealed that 100% acarbose (S1) had
significantly higher (p< 0.05) inhibitory effect (66.2± 0.7%)
than 100% gallic acid (S2; 43.9± 0.7%). However, considering
the combinations, a combination of 50% acarbose and 50%
gallic acid (S3) showed the highest significant (p< 0.05)
inhibitory effect (65.7± 1.4%), which was not significantly
different (p> 0.05) from the inhibitory effect of 100% acarbose.
The effect of gallic acid on a-amylase inhibitory activities
of acarbose is presented in Figure 3. The result revealed that
100% acarbose (S1) had significantly higher (p< 0.050 enzyme
inhibitory effect (82.8± 0.7%) than 100% gallic acid (S2;
49.0± 1.4%). It also showed that of the various combinations,
75% acarbose and 25% gallic acid (S4) had the highest signifi-
cant (p< 0.05) inhibitory effect (82.2± 1.6%); there was how-
ever, no significant difference (p> 0.05) in the inhibitory effect
of S4 and S1.100
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Figure 2 e Effect of gallic acid on a-glucosidase inhibitory
ability of acarbose (in vitro). Bars represent
mean± standard deviation of triplicate readings (n¼ 3).
* Mean values are significantly different (p< 0.05)
compared with S1. ** Mean values are significantly
different (p< 0.05) compared with S2. S1¼ 100% acarbose
(25mM); S2¼ 100% gallic acid (25mM); S3¼ 50%
acarboseþ 50% gallic acid; S4¼ 75% acarboseþ 25% gallic
acid; S5¼ 25% acarboseþ 75% gallic acid.The result of the Fe2þ chelating ability, as shown in
Figure 4, revealed that 100% acarbose (S1) had significantly
higher (p< 0.05) chelating ability (80.9± 1.3%) compared with
100% gallic acid (S2; 52.3± 3.2%). However, considering the
combinations, a combination of 75% acarbose and 25% gallic100
80
60
40
20
0
S1 S2 S3
Sample
*
*
** **
*
Fe
2+
 c
he
la
tin
g 
ab
ilit
y 
(%
)
S4 S5
Figure 4 e Effect of gallic acid on Fe2þ chelating ability of
acarbose (in vitro). Bars represent mean± standard
deviation of triplicate readings (n¼ 3). * Mean values are
significantly different (p< 0.05) compared with S1. ** Mean
values are significantly different (p< 0.05) compared with
S2. S1¼ 100% acarbose (25mM); S2¼ 100% gallic acid
(25mM); S3¼ 50% acarboseþ 50% gallic acid; S4¼ 75%
acarboseþ 25% gallic acid; S5¼ 25% acarboseþ 75% gallic
acid.
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Figure 6 e The effect of gallic acid on ferric reducing
antioxidant properties of acarbose (in vitro). Bars represent
mean± standard deviation of triplicate readings (n¼ 3).
* Mean values are significantly different (p< 0.05)
compared with S1. ** Mean values are significantly
different (p< 0.05) compared with S2. AAE¼ ascorbic acid
equivalent; S1¼ 100% acarbose (25mM); S2¼ 100% gallic
acid (25mM); S3¼ 50% acarboseþ 50% gallic acid; S4¼ 75%
acarboseþ 25% gallic acid; S5¼ 25% acarboseþ 75% gallic
acid.
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compared with other combinations, but was not significantly
different (p> 0.05) from the chelating ability (80.9± 1.3%) of
the combination of 25% acarbose and 75% gallic acid (S5).
Incubation of rat's pancreatic tissue homogenate in the
presence of 250mM FeSO4 induced a significant (p< 0.05) in-
crease (152.6± 0.7%) in the MDA content (Figure 5). However,
introduction of all the samples (S1eS5) inhibited lipid perox-
idation in the pancreatic tissue homogenates by causing a
significant (p< 0.05) reduction in the MDA content; neverthe-
less, there was no significant difference (p> 0.05) in the
inhibitory effects of 100% acarbose (S1; 61.7± 2.2%) and 100%
gallic acid (S2; 64.8± 0.7%). Considering the combinations, a
combination of 50% acarbose and 50% gallic acid (S3) caused
the highest significant (p< 0.05) reduction in the MDA content
(56.6± 0.7%).
The ferric reducing antioxidant properties of the samples
(S1eS5) were presented as AAE in Figure 6. The result revealed
that 100% acarbose had the highest significant (p< 0.05)
reducing property (319.7± 26.9mgAAE/g) comparedwith 100%
gallic acid (162.1± 22.5 mgAAE/g). However, a combination of
25% acarbose and 75% gallic acid (S5) had the highest signifi-
cant (p< 0.05) reducing property (403.2± 11.4 mgAAE/g)
compared with the other combinations, while the reducing
property of the combination of 50% acarbose and 50% gallic
acid (S3; 321.9± 10.1 mgAAE/g) showed no significant differ-
ence (p> 0.05) to that of 100% acarbose.
The result of the DPPH free radical scavenging ability
(Figure 7) revealed that 100% gallic acid (S2) had significantly
higher (p< 0.05) scavenging ability (69.2± 0.5%) compared
with 100% acarbose (S1; 42.5± 0.3%). However, a combination
of 50% acarbose and 50% gallic acid (S3) has the highest*
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Figure 5 e Effect of gallic acid on inhibition of Fe2þ induced
lipid peroxidation in rat's pancreas (in vitro) by acarbose.
Bars represent mean± standard deviation of triplicate
readings (n¼ 3). * Mean values are significantly different
(p< 0.05) compared with S1. ** Mean values are
significantly different (p< 0.05) compared with S2.
MDA¼malondialdehyde; S1¼ 100% acarbose (25mM);
S2¼ 100% gallic acid (25mM); S3¼ 50% acarboseþ 50%
gallic acid; S4¼ 75% acarboseþ 25% gallic acid; S5¼ 25%
acarboseþ 75% gallic acid.significant (p< 0.05) scavenging ability (73.2± 0.1%), but not
significantly different (p> 0.05) from the scavenging ability
(72.1± 0.1%) of the combination of 25% acarbose and 75% gallic
acid (S5).100
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Figure 7 e Effect of gallic acid on 2, 2-diphenyl-
1picrylhydrazyl (DPPH) radical scavenging ability of
acarbose (in vitro). Bars represent mean± standard
deviation of triplicate readings (n¼ 3). * Mean values are
significantly different (p< 0.05) compared with S1. ** Mean
values are significantly different (p< 0.05) compared with
S2. S1¼ 100% acarbose (25mM); S2¼ 100% gallic acid
(25mM); S3¼ 50% acarboseþ 50% gallic acid; S4¼ 75%
acarboseþ 25% gallic acid; S5¼ 25% acarboseþ 75% gallic
acid.
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Figure 8 e Effect of gallic acid on 2′-azino-bis(-3-
ethylbenzthiazoline-6-sulfonate (ABTS) radical scavenging
ability of acarbose (in vitro). Bars represent
mean± standard deviation of triplicate readings (n¼ 3).
S1¼ 100% acarbose (25mM); S2¼ 100% gallic acid (25mM);
S3¼ 50% acarboseþ 50% gallic acid; S4¼ 75%
acarboseþ 25% gallic acid; S5¼ 25% acarboseþ 75% gallic
acid. TEAC¼Trolox equivalent antioxidant capacity.
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Trolox equivalent antioxidatant capacity (Figure 8) revealed
that there was no significant difference (p> 0.05) in the ABTS*
scavenging ability of all the samples (S1¼ 25.67± 3.55 mmol-
TEAC/g; S2¼ 26.61± 3.55 mmolTEAC/g; S3¼ 25.69± 3.55
mmoLTEAC/g; S4¼ 26.63± 3.55 mmoLTEAC/g; and S5¼ 26.67
± 3.55 mmoLTEAC/g).4. Discussion
Hyperglycemia is a condition of abnormal rise in blood
glucose level and is an etiology of T2DM; a disease caused by
insulin resistance [35,36]. Acarbose is one of the therapeutic
drugs used to reduce postprandial hyperglycemia in T2DM
patients, but several side effects are observed during long
termuse [16,17]. Although the recommended therapeutic dose
of acarbose ranges from 150 mg/d to 600 mg/d depending on
the stage and severity of the diabetic condition [13], studies
have however, shown that the systemic absorption of acar-
bose is < 2% after oral dosing [15]; hence, the choice of a low
concentration of acarbose in this study. We therefore hy-
pothesize that combinations of acarbose with diets rich in
antidiabetic and antioxidant phenolic phytochemicals, such
as gallic acid, could help produce synergistic effects at
reducing postprandial rise in blood glucose level while at the
same time, offering possible reduction in the attendant side
effects of this drug. This is more so because previous studies
have reported the antihyperglycemic and antioxidant prop-
erties of phenolic rich food sources [37e39].
This study has revealed that acarbose, gallic acid, and their
various combinations caused the inhibition of both a-amylase
and a-glucosidase activities in vitro with 100% acarbose
exhibiting stronger inhibitory activities than the 100% gallicacid. A previous report has shown that acarbose serves as a
strong inhibitor of enzymes associated with carbohydrate
hydrolysis compared with phenolic compounds [9]. Specif-
ically, as presented in Figure 2, the combination of acarbose
and gallic acid in equal proportions had a higher a-glucosidase
inhibitory effect compared with 100% acarbose, a drug known
to be a strong inhibitor of a-glucosidase. Therefore, this
combination could be said to be synergistic, and could hence
serve as a possible combinatory therapy in preference to 100%
acarbose to possibly reduce the several side effects associated
with the use of acarbose.
Furthermore, the inhibitory effect of acarbose, gallic
acid, and their various combinations on a-amylase activity,
showed that acarbose inhibits a-amylase significantly more
than it inhibits a-glucosidase activity. Nevertheless, it ex-
hibits a stronger inhibiting property compared with gallic
acid, which showed mild inhibition of a-amylase. These
observations could be responsible in part for the side ef-
fects of acarbose and are also in agreement with previous
reports which indicated that excessive inhibition of
pancreatic a-amylase could result in the abnormal bacterial
fermentation of undigested carbohydrates in the colon;
and, therefore, mild a-amylase inhibition activity is desir-
able [40]. Therefore, since the combination of acarbose and
gallic acid at equal proportion serves as a mild inhibitor of
a-amylase and strong inhibitor of a-glucosidase, it could be
of great therapeutic importance in addressing the side ef-
fects associated with acarbose in the management of
T2DM, which is linked with excess inhibition of a-amylase.
Also, the combination of acarbose and gallic acid at the
ratio of 75:25 shows a synergistic inhibition of a-amylase.
Hence, the inhibition of these enzymes (a-glucosidase and
a-amylase) using the various combinations of acarbose and
gallic acid could be very effective in reducing hyperglyce-
mia and, hence, T2DM.
In addition, all the samples were able to chelate Fe2þ, with
the combinations of acarbose and gallic acid in the ratios of
75:25 and 25:75 having more Fe2þ chelating ability among the
various combinations. Fe2þ catalyzes one electron transfer
reactions that generates ROS such as the OH, which is formed
from H2O2 through the Fenton reaction. Iron causes lipid
peroxidation and also decomposes the lipid peroxides, which
leads to the generation of peroxyl and alkoxyl radicals, fa-
voring the propagation of lipid peroxidation [9]. In this study,
the incubation of rat pancreatic tissue homogenates in the
presence of 250 mM FeSO4 caused a significant (p< 0.05) in-
crease in the MDA content. Previous studies have also shown
that incubation of rat tissues in the presence of 250 mM FeSO4
solution caused a significant increase in their MDA content
[9,37]. However, the introduction of acarbose, gallic acid, and
their various combinations caused significant (p< 0.05)
decrease in the MDA content of the incubated pancreatic tis-
sue homogenate as shown in Figure 5. The possible mecha-
nism by which the samples protect against lipid peroxidation
could be by Fe2þ chelation [41]. Therefore, the decrease in the
pancreatic MDA content by acarbose, gallic acid, and their
various contributions could be attributed to their Fe2þ
chelating properties. However, a combination of 50% acarbose
and 50% gallic acid had the highest inhibitory effect on MDA
production.
j o u r n a l o f f o o d and d ru g an a l y s i s 2 4 ( 2 0 1 6 ) 6 2 7e6 3 4 633According to Li et al [42], pancreatic b-cells are vulnerable
to oxidative damage caused by ROS due to their limited anti-
oxidant defense systems. Antioxidants as diets, supplements,
or as nutraceuticals could help protect against the oxidative
damage and thus prevent diabetes and its complications.
Persistent hyperglycemia may induce free radical production
via glycation and autoxidation. This free radical production
contributes to b-cells destruction in T2DM [43].
The ability of phytochemicals possessing antioxidant
properties to reduce oxidative species has been shown to be
one of their antioxidative mechanisms [44]. The reducing
property of the samples was assessed based on their ability to
reduce Fe3þ to Fe2þ. The result reveals that the 100% acarbose
exhibits a higher ferric reducing ability than 100% gallic acid.
Of the various combinations, a combination of 25% acarbose
and 75% gallic acid shows the highest reducing property and
hence a synergistic effect. These observations could possibly
be attributed to the synergistic chemical reaction between the
phenolic acid (gallic acid) and acarbose.
Furthermore, this study also revealed that the samples
scavenged DPPH free radicals. One-hundred percent gallic
acid exhibited a higher radical scavenging ability than 100%
acarbose; nevertheless, a combination of 50% acarbose and
50% gallic acid showed the highest scavenging ability, hence
portraying a possible synergy in the DPPH free radical scav-
enging abilities of acarbose and gallic acid. The antioxidant
property of gallic acid has been previously reported [23];
hence, the presence of a phenolic compound (gallic acid) in
the various combinations could have enhanced their DPPH
scavenging abilities. The ability of gallic acid to act as a free
radical scavenger is due to the presence of multiple hydroxyl
groups in each compound which are able to donate their
protons to finally break the chain reaction of the free radicals
[45]. The ABTS radical scavenging ability result (Figure 8) re-
veals that there was no significant difference in the ABTS*
scavenging ability of all the samples (acarbose, gallic acid, and
their various combinations). Nevertheless, the samples were
able to scavenge the ABTSþ radical.
The free radical (ABTSþ and DPPH) scavenging abilities of
gallic acid, acarbose, and their various combinations could be
attributed to a structureefunction relationship; interactions
among their hydroxyl groups could contribute significantly to
their free radicals scavengign abilities [39].5. Conclusion
Conclusively, we have been able to show that gallic acid
influenced the in-vitro inhibitory properties of acarbose on key
enzymes (a-glucosidase and a-amylase) linked to T2DM. The
antioxidant properties of acarboseegallic acid combinations
could also be of unique therapeutic importance in managing
oxidative stress which is linked to diabetes. Therefore, com-
bination of gallic acid with acarbose could be employed in the
management of T2DM, with the comparative advantage of a
possible reduction of the side effects of acarbose; neverthe-
less, the combination of 50% acarbose and 50% gallic acid
seems the best. In view of this, diets rich in gallic acid could
serve as a means of managing diabetes. Furthermore, in cases
of chronic diabetes where drugs are to be taken, diets rich ingallic acid could be recommendedwith acarbose to reduce the
side effects associated with the drug; however, further in vivo
studies and clinical trials are recommended.Conflicts of interest
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